Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection

被引：172

作者：

Stone, TW ^{[1
]}

机构：

[1] Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland

来源：

TRENDS IN PHARMACOLOGICAL SCIENCES | 2000年 / 21卷 / 04期

关键词：

D O I：

10.1016/S0165-6147(00)01451-6

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Manipulation of the kynurenine pathway of tryptophan metabolism has yielded a plethora of agents that are now being developed as neuroprotectants and anticonvulsants. This pathway is involved in the production of the excitotoxin quinolinic acid and the neuroprotectant kynurenic acid. Approaches used in the development of therapeutic agents include production of analogues or pro-drugs of kynurenic acid and inhibitors of the enzyme responsible for the synthesis of quinolinic acid. Indeed, analogues of the amino acid receptor antagonist kynurenic acid are now in, or are about to enter, clinical trials for stroke and related disorders. This review summarizes the mechanism of action of these various agents, the development of glutamate receptor antagonists from kynurenic acid and the range of their potential uses in neurology and psychiatry.

引用

页码：149 / 154

页数：6

共 54 条

[1]

BARON BM, 1990, MOL PHARMACOL, V38, P554

[2]

BARON BM, 1992, J PHARMACOL EXP THER, V262, P947

[3] Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl [J].

Behan, WMH ;

McDonald, M ;

Darlington, LG ;

Stone, TW .

BRITISH JOURNAL OF PHARMACOLOGY, 1999, 128 (08) :1754-1760

[4] KYNURENIC ACID ANTAGONISES RESPONSES TO NMDA VIA AN ACTION AT THE STRYCHNINE-INSENSITIVE GLYCINE RECEPTOR [J].

BIRCH, PJ ;

GROSSMAN, CJ ;

HAYES, AG .

EUROPEAN JOURNAL OF PHARMACOLOGY, 1988, 154 (01) :85-87

[5] Protective and symptomatic strategies for therapy of Parkinson's disease [J].

Blandini, F ;

Greenamyre, JT .

DRUGS OF TODAY, 1999, 35 (06) :473-483

[6] Neuroprotective effects of RPR 104632, a novel antagonist at the glycine site of the NMDA receptor, in vitro [J].

Boireau, A ;

Malgouris, C ;

Burgevin, MC ;

Peny, C ;

Durand, G ;

Bordier, F ;

Meunier, M ;

Miquet, JM ;

Daniel, M ;

Chevet, T ;

Jimonet, P ;

Mignani, S ;

Blanchard, JC ;

Doble, A .

EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 300 (03) :237-246

[7] The glycine antagonist GV150526 protects somatosensory evoked potentials and reduces the infarct area in the MCAo model of focal ischemia in the rat [J].

Bordi, F ;

Pietra, C ;

Ziviani, L ;

Reggiani, A .

EXPERIMENTAL NEUROLOGY, 1997, 145 (02) :425-433

[8]

Bristow LJ, 1996, J PHARMACOL EXP THER, V277, P578

[9] 3-NITRO-3,4-DIHYDRO-2(1H)-QUINOLONES - EXCITATORY AMINO-ACID ANTAGONISTS ACTING AT GLYCINE-SITE NMDA AND (RS)-ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID RECEPTORS [J].

CARLING, RW ;

LEESON, PD ;

MOORE, KW ;

SMITH, JD ;

MOYES, CR ;

MAWER, IM ;

THOMAS, S ;

CHAN, T ;

BAKER, R ;

FOSTER, AC ;

GRIMWOOD, S ;

KEMP, JA ;

MARSHALL, GR ;

TRICKLEBANK, MD ;

SAYWELL, KL .

JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (22) :3397-3408

[10]

Carpenedo R., 1999, Society for Neuroscience Abstracts, V25, P2230

← 1 2 3 4 5 6 →